Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Labopharm's European subsidiary, Labopharm Europe Limited, has amended its licensing and distribution agreement with CSC Pharmaceuticals Handels GmbH for once-daily tramadol to include Russia. The amendment increases the number of countries covered by the agreement to 15.
Subscribe to our email newsletter
In 2004, Labopharm signed an agreement with CSC under which it granted CSC the exclusive right to market and sell Labopharm’s once-daily formulation of the pain drug tramadol in 14 central and eastern European countries, including Austria, Hungary and Romania.
Under terms of the agreement, Labopharm will generate revenue from product sales in Russia in line with the terms set out for the other 14 countries covered by the original agreement, as well as with the company’s other licensing and distribution agreements for Europe.
Labopharm will supply CSC with the finished packaged product through its Labopharm Europe subsidiary and will be responsible for obtaining regulatory approval in all countries covered by the agreement.
“With the expansion of our partnership with CSC to include Russia, which has a population of more than 142 million, we now have licensing and distribution agreements for our once-daily formulation of tramadol for 20 European countries, including four of the five largest markets,” said James Howard-Tripp, president and CEO of Labopharm Inc. “We are confident that with its strong market presence and regulatory expertise CSC will maximize the commercial opportunity inherent in our product.”